Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles

Area of Science:

• Oncology
• Nanotechnology
• Immunology

Background:

• Tumor-associated macrophages (TAMs) are key components of the tumor microenvironment and represent a promising therapeutic target.
• Current drug delivery systems lack specificity for TAMs, limiting their therapeutic potential.
• The
• eat me
• signal, phosphatidylserine (PS), plays a role in clearing apoptotic bodies via phagocytosis.

Purpose of the Study:

• To develop matrix metalloproteinase 2 (MMP2)-sensitive, PS-modified nanoparticles for targeted TAM phagocytosis.
• To evaluate the efficacy of these nanoparticles in delivering anticancer drugs to TAMs.
• To assess the potential of these nanoparticles as a tool for TAM-centered cancer therapy.

Main Methods:

• Engineered nanoparticles with externalized PS upon reaching MMP2-overexpressing tumor sites.
• Tested nanoparticle selectivity in various biological models: cell lines, cocultures, spheroids, zebrafish, and tumor-bearing mice.
• Loaded nanoparticles with the model drug dasatinib to assess TAM depletion and anticancer activity.

Main Results:

• Demonstrated excellent macrophage/TAM selectivity of the nanoparticles across all tested biological models.
• Achieved enhanced TAM depletion when dasatinib was loaded into the PS-modified nanoparticles.
• Observed improved anticancer activity due to the targeted drug delivery and TAM depletion.

Conclusions:

• MMP2-sensitive, PS-modified nanoparticles effectively target TAMs by mimicking apoptotic bodies.
• These nanoparticles show significant potential as a drug delivery system for enhancing cancer treatment efficacy.
• The developed nanoparticles represent a promising platform for TAM-centered cancer diagnosis and therapy.